Did you mean 9005 001 0?
Displaying drugs 626 - 650 of 1437 in total
Ethyl pyruvate
CTI-01 (ethyl pyruvate) is a novel anti-inflammatory agent for the treatment of critical inflammatory conditions. CTI-01 shows a potent anti-inflammatory and tissue protection activity in multiple animal models of disease including pancreatitis, ischemia-reperfusion injury, sepsis, renal injury and endotoxemia.
Investigational
Matched Description: … CTI-01 (ethyl pyruvate) is a novel anti-inflammatory agent for the treatment of critical inflammatory ... CTI-01 shows a potent anti-inflammatory and tissue protection activity in multiple animal models of …
Davanat
Davanat is under investigation in clinical trial NCT00054977 (Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors).
Investigational
Matched Description: … Davanat is under investigation in clinical trial NCT00054977 (Safety of GM-CT-01 With and Without 5-Fluorouracil …
Birabresib
Birabresib is under investigation in clinical trial NCT02698176 (A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)).
Investigational
Saruparib
Saruparib is under investigation in clinical trial NCT06380751 (Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or Palb2m Advanced Breast Cancer).
Investigational
Matched Description: … With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, …
4'-Thio-fac
4'-Thio-fac is under investigation in clinical trial NCT02661542 (Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas).
Investigational
Matched Description: … 4'-Thio-fac is under investigation in clinical trial NCT02661542 (Study of FF-10502-01 in Patients With …
Cavrotolimod
Investigational
Ivarmacitinib
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
Myristic acid
Experimental
Matched Mixtures name: … Jayjun Real Water Brightening Black Mask Step 01 Real Water Cleansing Foa M …
AP-001
Investigational
Panobacumab
Panobacumab is under investigation in clinical trial NCT00851435 (Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa).
Investigational
Zimberelimab
Investigational
Brogidirsen
Brogidirsen is under investigation in clinical trial NCT05996003 (NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)).
Investigational
MPT-0L055
Investigational
BPR-0L075
Investigational
BMN-044
Experimental
Withdrawn
Stamulumab
MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Investigational
BMX-001 free base
Investigational
TAK-075 Free base
Investigational
IKT-001Pro
Investigational
BMN-045
Experimental
Withdrawn
Dazukibart
Investigational
M-032
Investigational
MZE001
Investigational
MBP-091
MBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).
Investigational
Verzistobart
Verzistobart is under investigation in clinical trial NCT06056895 (Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma).
Investigational
Displaying drugs 626 - 650 of 1437 in total